Below is a comprehensive archive of press releases from MSF-USA. Use the options in the boxes below to filter results based on your preferences.

April 21, 2016

In advance of the next round of the Regional Comprehensive Economic Partnership (RCEP) negotiations starting in Perth, Australia, this Sunday, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is warning that current proposals in this trade agreement could severely restrict access to affordable medicines for millions of people around the world. Text from a leaked chapter on intellectual property shows that Japan and South Korea have made proposals that go beyond what international trade rules require, undermining access to affordable generic medicines and making it harder for patients and treatment providers like MSF to access affordable, lifesaving medicines.

April 12, 2016

More than fifty groups have come together to demand that the US Congress reject the Trans-Pacific Partnership Trade Deal (TPP) due to provisions it contains that would undermine public health. In a letter sent to Congress today, the groups outlined the damaging effects the trade deal would have on public health, and said lawmakers should not vote for the TPP unless damaging provisions are removed.

April 06, 2016

“Uncertain Tomorrow” Features Photos by Prize-winning Photographer William Daniels

March 11, 2016

New York/New Delhi—Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a "patent opposition" in India to block US pharmaceutical company Pfizer from patenting a pneumococcal conjugate vaccine, and ensure affordable access to this critical vaccine (PCV13). This is the first time a vaccine (biosimilar) patent has been challenged in India by a medical organization and, if successful, will make affordable versions of this lifesaving vaccine available to developing countries and humanitarian organizations.

March 10, 2016

Judit Rius Sanjuan, Access Campaign manager & legal policy advisor at Doctors Without Borders/Médecins Sans Frontières (MSF), made the following statement after KaloBios Pharmaceuticals obtained bankruptcy court permission to keep pursing a drug that could receive a US Federal Drug Administration Priority Review Voucher (PRV).

March 09, 2016

New York— A Senate committee voted today to add Zika to the list of diseases eligible for the US Federal Drug Administration (FDA) Priority Review Voucher (PRV) program for neglected diseases, but did not fix major loopholes that make the PRV program for neglected diseases ripe for abuse by pharmaceutical companies.

February 26, 2016

New York/New Delhi—In proceedings that could have major implications for millions of people waiting for affordable access to a lifesaving hepatitis C drug, the Indian Patent Office this week began hearings to determine whether US pharmaceutical company Gilead Sciences deserves a patent for sofosbuvir, a hepatitis C drug for which the company currently charges $1,000 per pill in the US.

February 24, 2016

International medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) today expressed great concern at the high price announced for the new tuberculosis (TB) drug delamanid. Japanese pharmaceutical company Otsuka said that it would make delamanid available to some developing countries at a price of $1,700 per treatment course.

February 10, 2016

Delhi/New York—A patient living with HIV in India has filed an application to try to block ViiV Healthcare from being granted patents on two new critical HIV drugs, the medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) announced today.

February 03, 2016

New YorkAs representatives from the United States and 11 other Pacific Rim countries gather in New Zealand Thursday to sign the Trans-Pacific Partnership (TPP) trade agreement, the fight to protect access to medicines in TPP countries is intensifying at the national level, with legislative processes starting that will determine if the deal is finally ratified and implemented.

Pages